pain therapeutics inc (PTIE) Key Developments
Pain Therapeutics Inc. Provides Update on Class Action Suit
Jun 29 15
On December 2, 2011, a securities-related purported class action was filed against Pain Therapeutics Inc. and its executive officers in the U.S. District Court for the Western District of Texas. This action, titled KB Partners I, L.P., Individually and on behalf of all others similarly situated v. Pain Therapeutics Inc., Remi Barbier, Nadav Friedmann and Peter S. Roddy, was scheduled for trial by court order dated June 23, 2015. Trial is to occur on July 7, 2015 through July 9, 2015 and continue on July 13, 2015 to July 14, 2015. In an order dated June 16, 2015, the U.S. District Court for the Western District of Texas denied a motion for summary judgment filed by Defendants concluding that there were genuine disputes of material fact for a jury to resolve in a class action alleging violations of Section 10(b), Rule 10b-5, and Section 20(a) of the Exchange Act. The company continue to believe it has substantial defenses in this matter. As with any litigation proceeding, it cannot predict with certainty the eventual outcome of this matter.
Pain Therapeutics Inc.(NasdaqGS:PTIE) dropped from Russell 2000 Index
Jun 29 15
Pain Therapeutics Inc. will be removed from Russell 2000 Index
Pain Therapeutics Inc.(NasdaqGS:PTIE) dropped from Russell 3000 Index
Jun 29 15
Pain Therapeutics Inc. will be removed from the Russell 3000 Index.
Pain Therapeutics Announces Positive Results from Drug Abuse Study
May 27 15
Pain Therapeutics Inc. announced positive results from an FDA Category 3 Human Abuse Potential Study with REMOXY extended-release capsules CII, which is designed to discourage certain common methods of drug tampering and misuse. This study demonstrated with statistical significance (p < 0.0001) that both intact and chewed REMOXY were less "liked" than immediate-release oxycodone on the two primary endpoints, Drug Liking and Drug High. The Abuse Potential study was conducted in non-dependent, recreational opioid users, as recommended by FDA guidelines.
Pain Therapeutics Inc. - Special Call
May 12 15
To discuss progress across its portfolio of drug candidates and to respond to questions